New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
18:11 EDTKOKeurig Green Mountain says 2.0 brewer introduced on time with retailer support
Says retailers aggressively ordered portion packs in Q4. Says brewer inventory levels "healthy" for upcoming holiday season. Says will run local, national TV ads during the holidays. Says Canadian business down for FY14. Says will offer 70 brands for brewers by March, 2015. Says on track to launch Keurig Cold in fall of 2015. Says working closely with Coca-Cola (KO) on cold brewing system. Says in FY15, expects growth in portion pack sales to accelerate as the year progresses. Says over 90% locked for coffee costs for FY15, but higher than FY14. Says coffee costs will be a headwind in 2Q15. Says expects some gross margin pressure in Q1. Says continues to expect long-term annual revenue, EPS growth in mid-teens. Comments from company's Q4 earnings conference call.
14:08 EDTKOEarnings Preview: Keurig Green Mountain sees FY14 EPS $3.71-$3.78
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:54 EDTNTRSExecutives' Club of Chicago to hold a meeting
CIO Murray of Northern Trust and Managing Director Larson of Accenture participate in a speech entitled, "Shifting Gears: Transforming to a Digital Enterprise in a meeting being held in Chicago on November 19 at 6 pm.
08:15 EDTKOGreat Lakes Coca-Cola Distribution signs definitive agreement with Coca-Cola
Subscribe for More Information
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
16:00 EDTKOOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
14:20 EDTKOCoca-Cola rumored to be in sights of 3G Capital, Forbes contributor reports
Investment firm 3G Capital is in advanced talks for a new fund targeted at the food and beverage industry, according to Veja magazine, reported a contributor to Forbes. The new fund could be used to acquire a significant stake in Coca-Cola or possibly even be used to orchestrate a takeover of the beverage giant, according to Veja columnist Geraldo Samor, the Forbes report said. Shares of Coca-Cola have moved into positive territory and are up 0.5% in afternoon trading following the circulation of the Forbes article. Reference Link
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
08:47 EDTSCHWCharles Schwab reports October net new assets $7.9B
The Charles Schwab Corporation released its Monthly Activity Report. Company highlights for the month of October 2014 include: Net new assets brought to the company by new and existing clients in October 2014 totaled $7.9B. Total client assets were $2.44T as of month-end October, up 12% from October 2013 and up 2% compared to September 2014. Average interest-earning assets on the company’s balance sheet were a record $141.5B as of month-end October, up 5% from October 2013 and up 1% compared to September 2014.
November 13, 2014
16:48 EDTPBYGabelli reports17.34% stake in Pep Boys
In light of the upcoming deadline to submit director nominations for consideration at the company's 2015 Annual Meeting of Shareholders, GAMCO, on behalf of its investment advisory clients, is considering interviewing potential candidates for nomination. If one or more of these individuals becomes a nominee for election as a director, GAMCO plans to cumulate its votes in favor of the election of such individual or individuals with the shares over which it has voting authority.
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
10:25 EDTKOSABMiller, Coca-Cola to form new company in Africa, Sky News reports
Mark Kleinman of Sky News tweeted, "SABMiller and Coca-Cola to announce formation of new company in Africa later this week, consolidating existing operations, I'm told."
10:07 EDTCMAHigh option volume stocks: DDS FOSL ZTS CMA CLVS CZR
Subscribe for More Information
09:37 EDTPBYGabelli raises stake in Pep Boys to 17.31% from 16.28%
Subscribe for More Information
November 10, 2014
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use